Paper25220191
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
Eng C and 3 others. Lancet, 2014. Cited by 299 papers, by iCite.
Cite this record
ConductScience Library. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Papers, record 25220191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25220191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Hypoglycemic Agents | Major topic |
| Insulin, Long-Acting | Major topic |
| Receptors, Glucagon | Major topic |
| Drug Therapy, Combination | |
| Glycated Hemoglobin | |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Weight Loss |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06894784 | A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | Background |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 25220193 | GLP-1 receptor agonists and basal insulin in type 2 diabetes. | https://conductscience.org/library/papers/25220193 | PubMed |
| Comment in | 25599366 | Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia. | https://conductscience.org/library/papers/25599366 | PubMed |
Cited by156
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 299 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42842067 | GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study. | Endocrine | 2026 | https://conductscience.org/library/papers/42842067 | PubMed |
| 42802751 | Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis. | J Diabetes Metab Disord | 2026 | https://conductscience.org/library/papers/42802751 | PubMed |
| 42277362 | Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis. | Curr Diab Rep | 2026 | https://conductscience.org/library/papers/42277362 | PubMed |
| 42153087 | Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. | Cureus | 2026 | https://conductscience.org/library/papers/42153087 | PubMed |
| 41465949 | Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. | Medicine (Baltimore) | 2025 | https://conductscience.org/library/papers/41465949 | PubMed |
| 39812791 | Glucagon-like peptide 1 receptor agonists outperform basal insulin in cardiovascular and renal outcomes for type 2 diabetes mellitus: a retrospective cohort study. | Acta Diabetol | 2025 | https://conductscience.org/library/papers/39812791 | PubMed |
| 38854306 | Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy. | Cureus | 2024 | https://conductscience.org/library/papers/38854306 | PubMed |
| 38792590 | De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test. | Life (Basel) | 2024 | https://conductscience.org/library/papers/38792590 | PubMed |
| 38633611 | Exenatide for obesity in children and adolescents: Systematic review and meta-analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38633611 | PubMed |
| 38433545 | [Fixed ratio combinations GLP-1RA and basal insulin: literature review]. | Probl Endokrinol (Mosk) | 2024 | https://conductscience.org/library/papers/38433545 | PubMed |
| 38253801 | Effects of Organic Zinc on the Growth Performance of Weanling Pigs: A Meta-analysis. | Biol Trace Elem Res | 2024 | https://conductscience.org/library/papers/38253801 | PubMed |
| 38249345 | Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38249345 | PubMed |
| 37990670 | Decreased cardiovascular risk factors and inflammation with remission of type 2 diabetes in adults with obesity using a high protein diet: Randomized control trial. | Obes Pillars | 2022 | https://conductscience.org/library/papers/37990670 | PubMed |
| 37864379 | The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial. | J Diabetes | 2023 | https://conductscience.org/library/papers/37864379 | PubMed |
| 37841938 | Anti-inflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37841938 | PubMed |
| 37362170 | Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022. | Clin Pediatr Endocrinol | 2023 | https://conductscience.org/library/papers/37362170 | PubMed |
| 37313232 | Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. | touchREV Endocrinol | 2023 | https://conductscience.org/library/papers/37313232 | PubMed |
| 37106129 | Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice. | Psychopharmacology (Berl) | 2023 | https://conductscience.org/library/papers/37106129 | PubMed |
| 37035222 | Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes. | World J Diabetes | 2023 | https://conductscience.org/library/papers/37035222 | PubMed |
| 36894921 | The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes. | Cardiovasc Diabetol | 2023 | https://conductscience.org/library/papers/36894921 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25220191
GET https://conductscience.org/api/papers/v1/25220191/cited_by?page=2